United Imaging's Thoracoabdominal Endoscopic Surgical Robot Receives NMPA Approval, Entering High-Growth Minimally Invasive Surgery Market

United Imaging Enters the Endoscopic Surgical Robot Track.

01

United Imaging Enters the Star Track

Endoscopic Surgical Robot Approved

National Medical Products Administration2026Year01Month05Japan Medical Device Approval Document Delivery InformationDisplay,Wuhan United Imaging Intelligence Healthcare Technology Co., Ltd.The thoracoabdominal endoscopic surgery system has been12Month31Approved on [Date]。

The official website of the company shows,United Imaging Intelligence is a subsidiary of United Imaging Group., mainly focusing on the research, development, production, and sales of intelligent diagnosis and treatment equipment and software, as well as related instruments and consumables., other approved products under its umbrella includePuncture Surgery Navigation and Positioning System、Neurosurgical Navigation and Positioning Systemetc.

In recent years, domestically produced surgical robotic systems for endoscopic procedures have been continuously approved. According to data from the National Medical Products Administration (NMPA), so far, they have been approved.Endoscopic SurgeryDomestic companies in the robotics field also includeWeigao,Edge Medical、Surui Robot、Minimally Invasive Medical、Sizherui、Condor Robot、Agile Medical、Rui Long Nuo Fu、TaoDao Medical、Conorth、Edge Medicaletc.

Previously,Mindray also publicly stated that itsEntering the surgical robot market with industrial chain advantages, aiming to become a world-class surgical robot.。

Globally, surgical robots are a highly sought-after business by major companies.

Last December,MedtronicProclamationClothUnder its umbrellaHugo™ Robotic-Assisted Urological Surgery System ObtainsFDAApproved for marketing.The Future Also PlansPlanHugo RASThe system's application in the United States is expanding to more surgical specialties. After the initial urology examination is passed, it is expected to be used in general and gynecological surgeries. Johnson & JohnsonSoft Tissue Surgical RobotOTTAVA also last yearCompletion of the first batch of patient clinical enrollment.

02

Acceleration of Commercialization

Chinese-Made Surgical Robots Continue to Advance

In the Chinese market, the surgical robot market is still continuously developing.According to Frost & SullivanData,2020Scale of China's Endoscopic Surgical Robot Market in [Year]318.4Million dollars, estimated2026Will reach by the year2315.3Million USD, with a compound annual growth rate during the period39.2%。

Policy End: National Healthcare Security AdministrationIn the guidelines for establishing surgical and therapeutic assistance operation categories,Will“Surgical Robot”“Remote Surgery”Unified Project Initiation, PushPrecision Medicine for Better ServicePatient.

Last year, the National Medical Products Administration released the "Measures to Optimize Lifecycle Regulation and Support Innovation and Development of High-End Medical Devices," which mentionedMedical RobotHigh-end medical imaging equipment, artificial intelligence medical devices, and new biomaterial medical devices are key areas for shaping the new quality productivity of medical devices.Fully support major innovations in high-end medical devices, promoting the application of more new technologies, new materials, new processes, and new methods in the healthcare field.

Currently, Da Vinci remains the dominant player in the global soft tissue surgical robot field.2025YearQ3Intuitive SurgicalIncome25.1Billion US dollars,Year-on-yearGrowth23%。

However, domestically produced surgical robots are also making active efforts. According to analysis by Toucan Research Institute,The cost advantage of domestically produced equipment is obvious.The cost of a single surgery can be reduced to that of the imported Da Vinci machine.50%–60%, Some surgical consumables have been controlled in1Within ten thousand yuan。

In terms of commercialization, domestically produced surgical robots have made initial progress.

According to the latest disclosure by MicroPort Robot,According to preliminary statistics within the group, itsTotal Global Commercial Orders for the Tu Mai Endoscopic Surgical Robot Exceed160Platform,2025New orders received in the year are close to120Platform, becomingThe First to Achieve 100 Commercial Installations in ChinaProductionCavity Endoscopic Surgical Robot. According to publicly available statistics, Tu Mai2025Ranked second globally in annual global order volume.

The capital market pays considerable attention to the surgical robot track.

2025Year12Month,SuruiRobotCompleted1USD billion financing。TheThis round of financing was led by Loyal Valley Capital, with continued additional investment from the Shanghai Biomedical Industry Fund, and joint participation from V Star Capital, D&H China Venture Capital, Hefei Industrial Investment, etc. In the same month,SuruiRobotObtained listing tutoring and filing registration, planned toAThighIPO。

In addition, newly approved last yearEdge Medical CompletedCompletedHundreds of millions of RMBBRound of Financing，Ruilong Surgical2025Total Financing AmountAlso Exceeded1Billion US dollars.

With the continuous increase in the penetration rate and usage frequency of endoscopic surgical robots, the industry is expected to further expand. At the same time, domestically produced surgical robots are actively "going global" to meet the comprehensive challenges of the international market.

END